SecurityGSK / GlaxoSmithKline plc
InstitutionPark National Corp /oh/
Shares6,367
Value $ 256,000
Related 377372AG2 / Glaxosmithkline Cap Inc. 0.70% 03/18/16
377372AH0 / Glaxosmithkline Cap Inc. 2.80% 03/18/23
377372AJ6 / Glaxosmithkline Cap Inc. 4.20% 03/18/43
377372AA5 / Glaxosmithkline Cap Inc Guaranteed Notes 4.375% 04/15/14
377372AB3 / Glaxosmithkline Cap Inc Guaranteed Notes 5.375% 04/15/34
377373AC9 / Glaxosmithkline Capital 1.50% 05/08/17
377373AD7 / Glaxosmithkline Capital 2.85% 05/08/22
377372AC1 / Glaxosmithkline Capital 4.85% Guaranteed Notes 5/15/13
377372AD9 / Glaxosmithkline Capital 5.65% Guaranteed Notes 5/15/18
377372AE7 / Glaxosmithkline Capital 6.375% Guaranteed Notes 5/15/38
377373AB1 / Glaxosmithkline Capital .75% 05/08/15

Park National Corp /oh/ reports 39.21% decrease in ownership of GSK / GlaxoSmithKline plc

July 02, 2018 - Park National Corp /oh/ has filed a 13F-HR form disclosing ownership of 6,367 shares of GlaxoSmithKline plc (NYSE:GSK) with total holdings valued at $256,000 USD as of June 30, 2018. Park National Corp /oh/ had filed a previous 13F-HR on April 02, 2018 disclosing 10,474 shares of GlaxoSmithKline plc at a value of $410,000 USD. This represents a change in shares of -39.21 percent and a change in value of -37.56 percent during the quarter.

Other investors with positions similar to Park National Corp /oh/ include Quadrant Capital Group Llc, General Re New England Asset Management Inc, Koshinski Asset Management, Inc., Fintrust Investment Advisory Services, Llc, Perigon Wealth Management, LLC, and Weil Company, Inc..

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR GlaxoSmithkline PLC Sponsored Com 37733W105 39.68 6,367 -39.21 256 -37.56 -163 9 2.18
2018-03-31 13F-HR GlaxoSmithkline PLC Sponsored Com 37733W105 37.29 10,474 26.24 410 39.46 81 35 11.84
2017-12-31 13F-HR GlaxoSmithkline PLC Sponsored Com 37733W105 38.01 8,297 -9.22 294 -20.75 -32 -45 -12.12
2017-09-30 13F-HR GlaxoSmithkline PLC Sponsored Com 37733W105 41.84 9,140 2.27 371 -3.64 8 -22 -5.84
2017-06-30 13F-HR GlaxoSmithkline PLC Sponsored Com 37733W105 42.60 8,937 41.54 385 44.74 112 7 2.73
2017-03-31 13F-HR GlaxoSmithkline PLC Sponsored Com 37733W105 40.27 6,314 1.90 266 11.76 5 23 9.77
2016-12-31 13F-HR GlaxoSmithkline PLC Sponsored Com 37733W105 40.73 6,196 -8.36 238 -18.21 -23 -30 -10.31
2016-09-30 13F-HR GlaxoSmithkline PLC Sponsored ADR Equity 37733W105 43.20 6,761 2.52 291 1.75 7 -2 -0.76
2016-06-30 13F-HR GlaxoSmithkline PLC Sponsored ADR Equity 37733W105 41.99 6,595 -4.70 286 1.78 -14 19 6.64
2016-03-31 13F-HR GlaxoSmithkline Equity 037733W10 40.44 6,920 8.04 281 8.91 21 2 0.84
2015-12-31 13F-HR GlaxoSmithkline Equity 037733W10 6,405 258


CUSIP: 37733W105